FDA employees return to work
FDA employees return to work - News - PharmaTimes
by Kevin Grogan
www.pharmatimes.com/news/fda_employees_return_to_work_1005871FDA employees return to work - News - PharmaTimes
by Kevin Grogan
www.pharmatimes.com/news/fda_employees_return_to_work_1005871It has been reported by Bloomberg that Pharmacyclics, which discovered the cancer drug Imbruvica, is looking for buyers and partner Johnson & Johnson and Novartis are cited as possible acquirers. - News - PharmaTimes
by Kevin Grogan
www.pharmatimes.com/news/pharmacyclics_up_for_sale_bloomberg_971114The UK's Acacia Pharma has raised £15 million to finance late-stage development of its treatments designed to prevent nausea and vomiting in cancer patients. - News - PharmaTimes
by Kevin Grogan
www.pharmatimes.com/news/acacia_raises_15_million_1005626Ireland-based clinical research organisation giant Icon has completed its $143.5 million acquisition of Aptiv Solutions. - News - PharmaTimes
by Kevin Grogan
www.pharmatimes.com/news/icon_seals_acquisition_of_aptiv_1001917UCB has acquired the key pharmaceutical assets of the UK's Lectus Therapeutics, boosting its efforts in the central nervous system field. - News - PharmaTimes
by Kevin Grogan
www.pharmatimes.com/news/ucb_acquires_lectus_assets_980012Ferring Pharmaceuticals has acquired the assets of the USA’s BioSurface Engineering Technologies (BioSET), including two Phase III-ready ‘orthobiologics’ designed to improve bone repair. - News - PharmaTimes
by Kevin Grogan
www.pharmatimes.com/news/ferring_buys_biosets_orthobiologics_971064Eli Lilly has entered into a collaboration with Japan's PeptiDream to discover and develop novel therapeutic peptides. - News - PharmaTimes
by Kevin Grogan
www.pharmatimes.com/news/lilly_links_up_with_japans_peptidream_1006215Actavis will pull out of China because it is not "worth the aggravation", chief executive Paul Bisaro has told Bloomberg. - News - PharmaTimes
by Kevin Grogan
www.pharmatimes.com/news/actavis_to_pull_out_of_china_1001367AstraZeneca has completed the sale of the assets of its subsidiary, Aptium Oncology. - News - PharmaTimes
by Kevin Grogan
www.pharmatimes.com/news/az_divests_atrium_oncology_unit_977000Pfizer has finally found a buyer for its Sandwich site in Kent, having completed the sale to a private consortium. - News - PharmaTimes
by Kevin Grogan
www.pharmatimes.com/news/pfizer_sells_sandwich_site_976851